Literature DB >> 7925203

Early and late reversibility of rocuronium bromide.

L van den Broek1, J H Proost, J M Wierda.   

Abstract

A computer simulation has been developed based on pharmacodynamic-pharmacokinetic modelling of the effect of neostigmine on rocuronium-induced neuromuscular blockade. The results of a previous study involving 60 patients were used as a test of the model. The model predicts that administration of neostigmine 40 micrograms kg-1 within 20 min of the administration of rocuronium does not decrease the duration of the block until 90% recovery has taken place. The optimum dose of neostigmine depends on the degree of block at the time of administration: for a more intense block the optimum dose is 80 micrograms kg-1 and for a less intense block is about 30 micrograms kg-1. The pharmacokinetic behaviour rather than the potency of the relaxant determines its reversibility.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7925203

Source DB:  PubMed          Journal:  Eur J Anaesthesiol Suppl        ISSN: 0952-1941


  3 in total

Review 1.  Newer neuromuscular blocking agents: how do they compare with established agents?

Authors:  H J Sparr; T M Beaufort; T Fuchs-Buder
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 2.  [Sugammadex. New pharmacological concept for antagonizing rocuronium and vecuronium].

Authors:  H J Sparr; L H Booij; T Fuchs-Buder
Journal:  Anaesthesist       Date:  2009-01       Impact factor: 1.041

3.  Comparative study between sugammadex and neostigmine in neurosurgical anesthesia in pediatric patients.

Authors:  Ayman A Ghoneim; Mohammed A El Beltagy
Journal:  Saudi J Anaesth       Date:  2015 Jul-Sep
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.